Janux Therapeutics, Inc.

NasdaqGM JANX

Janux Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2024

Janux Therapeutics, Inc. Operating Income is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.

Janux Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -75.11 M, a -20.53% change year over year.
Janux Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -62.31 M, a -195.42% change year over year.
Janux Therapeutics, Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -21.09 M.

Key data

Date	Operating Income	EBIT	EBITDA	Net Income

NasdaqGM: JANX

Janux Therapeutics, Inc.

CEO	Dr. David Alan Campbell Ph.D.
IPO Date	June 11, 2021
Location	United States
Headquarters	11099 North Torrey Pines Road
Employees	76
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals Robotics Vaccines

Description

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Key trends

Past 5 years